Oventus Medical Ltd (ASX: OVN) conducted its AGM today:
- Significant progress was made in commercialising the new treatment platform for Obstructive Sleep Apnoea in the previous year.
- OVN achieved major milestones- the launch of its ‘lab in lab’ clinical delivery model to streamline patients’ access to treatment by ensuring the sleep physician as well as dentist work together in the care of the patient, promoting choice, early intervention and support through their treatment.
- Launched first five sites in October 2019 and OVN is in process of deploying a further 8 sites.
- Additional contracts were signed with sleep groups in California and North Carolina.
- Its latest product, the O2Vent® Optima was launched in Canada as well as Australia.